Filing Flows › Agios Pharmaceuticals (AGIO) › Q1 2025
Agios Pharmaceuticals (AGIO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Agios Pharmaceuticals (AGIO) reported revenue of $8.7M for the first quarter 2025 (Q1 2025), +7% from a year earlier and -19% from the quarter before.
Agios Pharmaceuticals, Q1 2025: revenue $8.7M (+7% year over year), net loss $89.3M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.7M | -19% | +7% |
| Operating profit | −$107M | — | — |
| Net earnings | −$89.3M | — | — |
| Operating cash flow | −$111M | — | — |
What changed
Revenue was $8.7M in Q1 2025, up 7% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $106.6M, an operating margin of -1222.0%. Total costs grew 15% against revenue growth of 7%. The fastest-growing cost line was Cost of revenue (+73%). The quarter ended with a net loss of $89.3M, narrower than the previous quarter's $96.5M loss.
Operating cash flow was −$111.5M. Non-cash charges added back $11.4M of share-based compensation. Working capital and other items used $33.6M. Capital expenditures of $766K exceeded it, leaving free cash flow of −$112.3M.
Questions
What was Agios Pharmaceuticals' revenue in the first quarter 2025?
Agios Pharmaceuticals (AGIO) reported revenue of $8.7M for the first quarter 2025 (Q1 2025), +7% from a year earlier and -19% from the quarter before.